title: Fluconazole prophylaxis prevents invasive fungal infection in high-risk, very low birth weight infants.
abstract: OBJECTIVE
  To evaluate the benefit of fluconazole prophylaxis in preventing invasive fungal infection in very low birth weight (VLBW) infants with central vascular access.
  
  
  METHODS
  A 3-year baseline period (1998 to 2000) was compared with a subsequent 3-year period (2001 to 2003) during which a different protocol for preventing invasive fungal infection was used. All infants with a birth weight < 1500 g and with central vascular access were eligible for the study. Fluconazole (Diflucan R) was administered for 28 days at a dose of 6 mg/kg every third day during the first week and daily after the first week.
  
  
  RESULTS
  There were no significant differences between the baseline and the fluconazole groups in demographic characteristics or risk factors for fungal infection. Fungal infection developed in 9 of the infants in the baseline group and in none of those in the fluconazole group (P=.003). A trend of decreasing mortality rate between the 2 groups (12.6% vs 8.1%; P=.32) was observed but was not statistically significant. No adverse effects of fluconazole therapy were documented.
  
  
  CONCLUSIONS
  Fluconazole prophylaxis appeared to be beneficial in preventing invasive fungal infection in VLBW infants.
authors.affiliation: Department of Critical Care Medicine and Surgery, Division of Neonatology, University of Florence School of Medicine, Careggi University Hospital, Florence, Italy. giovanna.bertini@unifi.it
authors.forename: Giovanna
authors.initials: G
authors.lastname: Bertini
authors.forename: Silvia
authors.initials: S
authors.lastname: Perugi
authors.forename: Carlo
authors.initials: C
authors.lastname: Dani
authors.forename: Luca
authors.initials: L
authors.lastname: Filippi
authors.forename: Simone
authors.initials: S
authors.lastname: Pratesi
authors.forename: Firmino F
authors.initials: FF
authors.lastname: Rubaltelli
mesh_terms: D000935:Antifungal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002177:Candidiasis / Q000517:prevention & control*; D002986:Clinical Trials as Topic; D003428:Cross Infection / Q000517:prevention & control*; D004334:Drug Administration Schedule; D005260:Female; D015725:Fluconazole / Q000008:administration & dosage / Q000627:therapeutic use*; D005865:Gestational Age; D006801:Humans; D007231:Infant, Newborn; D019102:Infant, Very Low Birth Weight; D007363:Intensive Care Units, Neonatal; D008297:Male; D012307:Risk Factors
chemical_list: D000935:Antifungal Agents; D015725:Fluconazole